Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX) announced that a webcast featuring CEO Mike Raab and CCO Susan Rodriguez will take place at the Piper Sandler 32nd Annual Virtual Healthcare Conference today at 10 a.m. ET. The webcast can be accessed on the Ardelyx website under the Events and Presentations section, with a replay available for 60 days post-presentation. Ardelyx is currently advancing tenapanor for controlling serum phosphorus in CKD patients on dialysis, with an FDA NDA review and a PDUFA date set for April 29, 2021. The company also focuses on hyperkalemia treatments and has established international partnerships.
- None.
- None.
FREMONT, Calif., Nov. 23, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that a webcast of Mike Raab, president and chief executive officer of Ardelyx, and Susan Rodriguez, chief commercial officer, participating in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference will be available today at 10 a.m. ET.
To access the webcast of Ardelyx's presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the fireside chat will be available on the Ardelyx website for 60 days following the presentation.
About Ardelyx, Inc.
Ardelyx is focused on developing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiovascular diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue program, for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference-301178393.html
SOURCE Ardelyx
FAQ
What time is Ardelyx's presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference?
Where can I access the Ardelyx webcast?
What is the PDUFA date for Ardelyx's NDA review of tenapanor?
What are Ardelyx's key product candidates?
When was IBSRELA approved by the FDA?
